| scholarly article | Q13442814 |
| P2093 | author name string | Sedigheh Zakeri | |
| Navid D Djadid | |||
| Akram A Mehrizi | |||
| Sakineh Pirahmadi | |||
| Zahra Ghorbanzadeh | |||
| Abbas-Ali Raz | |||
| Jafar J Sani | |||
| Ronak Abbasi | |||
| P2860 | cites work | Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. | Q52039946 |
| Recent primary toxoplasma infection indicated by a low avidity of specific IgG | Q69965647 | ||
| Clinical setbacks for toll-like receptor 9 agonists in cancer | Q80768929 | ||
| Expression of toll-like receptors on B lymphocytes | Q81270307 | ||
| Heterogeneity in the acquisition of naturally acquired antibodies to cell-traversal protein for ookinetes and sporozoites (CelTOS) and thrombospondin-related adhesion protein (TRAP) of Plasmodium falciparum in naturally infected patients from unstab | Q90449851 | ||
| A study in clinical cancer immunotherapy | Q93806199 | ||
| Immune mechanisms in malaria: new insights in vaccine development | Q21032484 | ||
| Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3 | Q27860854 | ||
| Discovery of Novel Plasmodium falciparum Pre-Erythrocytic Antigens for Vaccine Development | Q27972709 | ||
| Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites | Q28212476 | ||
| Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants | Q28256294 | ||
| The RTS,S malaria vaccine | Q28285472 | ||
| Immunization with Pre-Erythrocytic Antigen CelTOS from Plasmodium falciparum Elicits Cross-Species Protection against Heterologous Challenge with Plasmodium berghei | Q28749621 | ||
| CelTOS, a novel malarial protein that mediates transmission to mosquito and vertebrate hosts | Q30045410 | ||
| A Research Agenda to Underpin Malaria Eradication | Q33818020 | ||
| A research agenda for malaria eradication: vaccines | Q33818046 | ||
| Malaria transmission-blocking vaccines--how can their development be supported? | Q33853275 | ||
| Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial | Q34043843 | ||
| Malaria vaccine R&D in the Decade of Vaccines: breakthroughs, challenges and opportunities | Q34340186 | ||
| Can successful vaccines teach us how to induce efficient protective immune responses? | Q34409182 | ||
| Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates | Q34416103 | ||
| Targeting the non-structural protein 1 from dengue virus to a dendritic cell population confers protective immunity to lethal virus challenge | Q34855420 | ||
| Computational and experimental validation of B and T-cell epitopes of the in vivo immune response to a novel malarial antigen | Q34971618 | ||
| Humoral immune responses of Solomon Islanders to the merozoite surface antigen 2 of Plasmodium falciparum show pronounced skewing towards antibodies of the immunoglobulin G3 subclass | Q35544545 | ||
| Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides | Q35642602 | ||
| CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections | Q35713871 | ||
| Helping the CD8(+) T-cell response | Q35852274 | ||
| HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost | Q35883997 | ||
| Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults | Q36165265 | ||
| Polio Eradication From the Western Hemisphere | Q36183074 | ||
| Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines | Q36362230 | ||
| Recent advances in recombinant protein-based malaria vaccines | Q36394182 | ||
| The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine | Q36497412 | ||
| Evidence for environmental modulation of gametocytogenesis in Plasmodium falciparum in continuous culture | Q36674691 | ||
| Self-adjuvanting bacterial vectors expressing pre-erythrocytic antigens induce sterile protection against malaria | Q36981626 | ||
| Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy. | Q36981682 | ||
| The World Health Organization and global smallpox eradication | Q37014608 | ||
| Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant | Q37273249 | ||
| Malaria parasite CelTOS targets the inner leaflet of cell membranes for pore-dependent disruption | Q37462647 | ||
| Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. | Q37497786 | ||
| The Plasmodium falciparum Cell-Traversal Protein for Ookinetes and Sporozoites as a Candidate for Preerythrocytic and Transmission-Blocking Vaccines | Q37611985 | ||
| Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors | Q37641401 | ||
| New adjuvants for human vaccines | Q37751473 | ||
| CpG oligodeoxynucleotides as TLR9 agonists: therapeutic application in allergy and asthma | Q37771931 | ||
| Use of defined TLR ligands as adjuvants within human vaccines. | Q37825528 | ||
| Trends in vaccine adjuvants. | Q37867107 | ||
| Circumsporozoite proteins of malaria parasites | Q38151503 | ||
| The path of malaria vaccine development: challenges and perspectives | Q38196455 | ||
| Improved synchronous production of Plasmodium falciparum gametocytes in vitro | Q39005607 | ||
| Production of interleukin 10 during malaria caused by lethal and nonlethal variants of Plasmodium yoelii yoelii | Q39142470 | ||
| Tumor necrosis factor in Plasmodium falciparum malaria: high plasma level is associated with fever, but high production capacity is associated with rapid fever clearance. | Q40654567 | ||
| Toward the rational design of a malaria vaccine construct using the MSP3 family as an example: contribution of immunogenicity studies in models | Q42947548 | ||
| Malaria vaccine technology roadmap | Q43650366 | ||
| Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS. | Q44189645 | ||
| Cutting edge: priming of CD8 T cell immunity to herpes simplex virus type 1 requires cognate TLR3 expression in vivo | Q45123319 | ||
| Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults | Q45423583 | ||
| Toll-like receptor 3 promotes cross-priming to virus-infected cells. | Q45511446 | ||
| malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication | Q47134819 | ||
| IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. | Q47830190 | ||
| Schistosoma mansoni infection cancels the susceptibility to Plasmodium chabaudi through induction of type 1 immune responses in A/J mice | Q47869317 | ||
| Polyinosinic-polycytidylic acid limits tumor outgrowth in a mouse model of metastatic lung cancer. | Q47881125 | ||
| Malaria vaccine candidate antigen targeting the pre-erythrocytic stage of Plasmodium falciparum produced at high level in plants | Q47882452 | ||
| Immune responses elicited by co-immunization of Plasmodium vivax and P. falciparum MSP-1 using prime-boost immunization strategies | Q47989426 | ||
| Re-investigation of the circumsporozoite protein-based induction of sterile immunity against Plasmodium berghei infection | Q48031921 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | parasitology | Q180502 |
| Plasmodium falciparum | Q311383 | ||
| Anopheles stephensi | Q4115863 | ||
| infectious disease | Q18123741 | ||
| ookinete | Q123923963 | ||
| P304 | page(s) | 146 | |
| P577 | publication date | 2019-04-24 | |
| P1433 | published in | Malaria Journal | Q15749954 |
| P1476 | title | Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi | |
| P478 | volume | 18 |
Search more.